Datroway, AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate, showed prolonged survival in patients with advanced triple-negative breast cancer who are ineligible for immunotherapy. This Phase 3 success may position Datroway as a chemotherapy alternative in this aggressive cancer subtype. The results add to clearances in other breast and lung malignancies, signaling a growing role for targeted antibody therapies in hard-to-treat cancers.